Next Article in Journal
Advances in Plant Autophagy
Next Article in Special Issue
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Previous Article in Journal
Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival
Previous Article in Special Issue
Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients—Comparison with the Standard Histopathological Procedure
Open AccessReview

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer

1
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
2
Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy
3
Interdisciplinary Group for Translational Research and Clinical Trials, Urological Cancers (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy
*
Author to whom correspondence should be addressed.
Cells 2021, 10(1), 193; https://doi.org/10.3390/cells10010193
Received: 16 December 2020 / Revised: 11 January 2021 / Accepted: 13 January 2021 / Published: 19 January 2021
(This article belongs to the Special Issue Identification of Prognostic Markers in Cancer Biology)
Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical treatments inevitably develop metastatic disease. Patient stratification is therefore key in this type of cancer, and there is an urgent need for prognostic biomarkers that can define patients’ risk of cancer-related death. In the last 10 years, multiple prognostic factors have been identified and studied. Here, we review the literature available and discuss the most common aberrant genomic pathways in metastatic castration-resistant prostate cancer shown to have a prognostic relevance in this setting. View Full-Text
Keywords: prostate cancer; androgen receptor; PTEN; DNA repair defects; prognostic biomarkers prostate cancer; androgen receptor; PTEN; DNA repair defects; prognostic biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Conteduca, V.; Mosca, A.; Brighi, N.; de Giorgi, U.; Rescigno, P. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. Cells 2021, 10, 193. https://doi.org/10.3390/cells10010193

AMA Style

Conteduca V, Mosca A, Brighi N, de Giorgi U, Rescigno P. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. Cells. 2021; 10(1):193. https://doi.org/10.3390/cells10010193

Chicago/Turabian Style

Conteduca, Vincenza; Mosca, Alessandra; Brighi, Nicole; de Giorgi, Ugo; Rescigno, Pasquale. 2021. "New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer" Cells 10, no. 1: 193. https://doi.org/10.3390/cells10010193

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop